1. Home
  2. TMQ vs URGN Comparison

TMQ vs URGN Comparison

Compare TMQ & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

HOLD

Current Price

$5.70

Market Cap

785.2M

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$19.99

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMQ
URGN
Founded
2004
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
785.2M
922.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TMQ
URGN
Price
$5.70
$19.99
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$29.50
AVG Volume (30 Days)
6.6M
728.3K
Earning Date
02-12-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$96,516,000.00
Revenue This Year
N/A
$26.47
Revenue Next Year
N/A
$110.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.00
52 Week Low
$1.13
$3.42
52 Week High
$11.29
$30.00

Technical Indicators

Market Signals
Indicator
TMQ
URGN
Relative Strength Index (RSI) 52.42 44.27
Support Level $4.93 $18.97
Resistance Level $7.25 $22.07
Average True Range (ATR) 0.60 1.31
MACD -0.10 0.06
Stochastic Oscillator 31.25 49.24

Price Performance

Historical Comparison
TMQ
URGN

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: